Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives

Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zulfikar, Sabrina, Mulholland, Sarah, Adamali, Huzaifa, Barratt, Shaney L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367740/
https://www.ncbi.nlm.nih.gov/pubmed/32765123
http://dx.doi.org/10.2147/CPAA.S228362
_version_ 1783560476609740800
author Zulfikar, Sabrina
Mulholland, Sarah
Adamali, Huzaifa
Barratt, Shaney L
author_facet Zulfikar, Sabrina
Mulholland, Sarah
Adamali, Huzaifa
Barratt, Shaney L
author_sort Zulfikar, Sabrina
collection PubMed
description Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.
format Online
Article
Text
id pubmed-7367740
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73677402020-08-05 Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives Zulfikar, Sabrina Mulholland, Sarah Adamali, Huzaifa Barratt, Shaney L Clin Pharmacol Review Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease. Dove 2020-07-13 /pmc/articles/PMC7367740/ /pubmed/32765123 http://dx.doi.org/10.2147/CPAA.S228362 Text en © 2020 Zulfikar et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Zulfikar, Sabrina
Mulholland, Sarah
Adamali, Huzaifa
Barratt, Shaney L
Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_full Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_fullStr Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_full_unstemmed Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_short Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_sort inhibitors of the autotaxin-lysophosphatidic acid axis and their potential in the treatment of interstitial lung disease: current perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367740/
https://www.ncbi.nlm.nih.gov/pubmed/32765123
http://dx.doi.org/10.2147/CPAA.S228362
work_keys_str_mv AT zulfikarsabrina inhibitorsoftheautotaxinlysophosphatidicacidaxisandtheirpotentialinthetreatmentofinterstitiallungdiseasecurrentperspectives
AT mulhollandsarah inhibitorsoftheautotaxinlysophosphatidicacidaxisandtheirpotentialinthetreatmentofinterstitiallungdiseasecurrentperspectives
AT adamalihuzaifa inhibitorsoftheautotaxinlysophosphatidicacidaxisandtheirpotentialinthetreatmentofinterstitiallungdiseasecurrentperspectives
AT barrattshaneyl inhibitorsoftheautotaxinlysophosphatidicacidaxisandtheirpotentialinthetreatmentofinterstitiallungdiseasecurrentperspectives

Ejemplares similares